ABIONYX Pharma And 2 Other Promising European Penny Stocks

The European market has recently experienced a week of volatility, with the pan-European STOXX Europe 600 Index remaining largely unchanged amid fluctuations in tech stocks and rising oil prices. In this context, penny stocks—often associated with smaller or emerging companies—continue to capture investor interest due to their potential for growth at lower price points. Despite being an older term, penny stocks still offer opportunities when they are backed by strong financials and solid fundamentals. This article explores several European penny stocks that may provide both stability and upside potential.

Below we spotlight a couple of our favorites from our exclusive screener.

ABIONYX Pharma (ENXTPA:ABNX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ABIONYX Pharma SA is a biotech company focused on developing therapies for renal, metabolic, and ophthalmic diseases in France and the United States, with a market cap of €67.76 million.

Operations: The company generates revenue from its CRO Activity, amounting to €4.06 million.

Market Cap: €67.76M

ABIONYX Pharma, with a market cap of €67.76 million, is navigating the biotech sector by focusing on developing therapies for critical diseases. Despite generating €4.06 million in revenue from its CRO activities, the company remains unprofitable and forecasts indicate continued challenges in achieving profitability over the next three years. Recent strategic moves include an €18.7 million follow-on equity offering to bolster its financial runway and support ongoing clinical trials for CER-001, targeting sepsis and LCAT deficiency. The company's efforts are geared towards establishing CER-001 as a new standard of care while managing cash flow constraints effectively.

• Dive into the specifics of ABIONYX Pharma here with our thorough balance sheet health report.
• Assess ABIONYX Pharma's future earnings estimates with our detailed growth reports.

Cellectis (ENXTPA:ALCLS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cellectis S.A. is a clinical-stage biotechnological company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for other therapeutic areas, with a market cap of €181.50 million.

Operations: The company's revenue is derived entirely from its Therapeutics segment, amounting to $75.11 million.

Market Cap: €181.5M

Cellectis S.A., with a market cap of €181.50 million, is advancing in the biotech arena through its gene-editing products, focusing on immuno-oncology and gene therapy. Despite being unprofitable and not expected to achieve profitability soon, it has a robust cash position with short-term assets exceeding liabilities. Recent clinical trials for lasme-cel and eti-cel show promising results in heavily pretreated cancer patients, supported by FDA's RMAT designation for lasme-cel. The company trades significantly below estimated fair value but faces challenges like high volatility and increasing debt-to-equity ratio over recent years.

• Take a closer look at Cellectis' potential here in our financial health report.
• Examine Cellectis' earnings growth report to understand how analysts expect it to perform.

Merus Power Oyj (HLSE:MERUS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Merus Power Oyj, with a market cap of €40.02 million, designs, manufactures, and sells electrical engineering solutions in Finland, Europe, and internationally.

Operations: The company's revenue is derived from its Electric Equipment segment, which generated €56.07 million.

Market Cap: €40.02M

Merus Power Oyj, with a market cap of €40.02 million, is actively expanding its footprint in the energy storage sector through strategic projects like the recent €8 million order for a 20 MW/41 MWh battery energy solution at Varevaara wind farm. Despite being unprofitable and having negative return on equity (-10.72%), Merus Power shows potential with forecasted earnings growth of 65.1% per year and reduced debt-to-equity ratio from 171.8% to 76% over five years. The company’s short-term assets (€22.4M) comfortably cover both short-term (€12.7M) and long-term liabilities (€5.7M).

• Get an in-depth perspective on Merus Power Oyj's performance by reading our balance sheet health report here.
• Explore Merus Power Oyj's analyst forecasts in our growth report.

Taking Advantage

• Click through to start exploring the rest of the 307 European Penny Stocks now.
• Interested In Other Possibilities? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com